YOU ARE HERE: LAT HomeCollectionsParkinson S Disease

Parkinson S Disease

June 23, 2005 | Denise Gellene, Times Staff Writer
A second set of participants in an aborted clinical trial has filed a federal lawsuit against Amgen Inc., seeking access to an experimental Parkinson's disease drug. Amgen withdrew the drug in September, saying it was no better than a placebo and could be harmful. The patients said the drug GDNF had helped them. The lawsuit was filed Tuesday in U.S. District Court in Lexington, Ky., by eight patients who were treated at the University of Kentucky Medical Center.
March 31, 2003 | From Times Wire Reports
A preliminary trial on the safety of a drug for use by those with Parkinson's disease surprised scientists when all five patients in the test showed measurable improvement. The drug, GDNF, eliminated the periods of immobility that had occurred as much as 20% of the time before treatment and reduced or stopped the involuntary movements common to the disease, said Clive N. Svendsen of the University of Wisconsin Madison. The findings are in the online issue of Nature Medicine.
July 1, 2006 | From Times Staff and Wire Reports
People with long-term low-level exposure to pesticides have a 70% higher incidence of Parkinson's disease than people who have not been exposed much to bug sprays, U.S. researchers have reported. Such people include farmers, ranchers and fishermen, the researchers report in the July issue of Annals of Neurology.
April 11, 1987 | THOMAS H. MAUGH II, Times Science Writer
Surgeons at Vanderbilt University here rushed ahead with a pioneering brain graft surgery within two weeks of publication of an article in the New England Journal of Medicine suggesting that the technique developed by Mexican researchers could reverse the effects of Parkinson's disease. "It is important that somebody confirm (the Mexican) results as soon as possible," neurosurgeon George S. Allen, leader of the Vanderbilt team, said Friday.
December 11, 1989 | From Times Staff and Wire Reports
Scientists say they have detected a blood cell defect in people with Parkinson's disease, a link that could help identify victims before symptoms appear. Such timely identification, they say, could open the door for earlier treatment of the disease that afflicts 400,000 Americans. The findings, published in the Annals of Neurology, are the product of federally funded research at the University of Colorado Health Sciences Center.
Don Nelson didn't think of himself as a pioneer on that November day nearly two years ago when the Denver surgical team began to numb his head in preparation for brain-transplant surgery. The former factory manager, then 52, knew only that the ravages of more than two decades of Parkinson's disease had left him abruptly paralyzed several times a day. "I had no alternative," he says. "Nothing else was working."
April 16, 2007 | From Times wire reports
People from families prone to Parkinson's who drink coffee or smoke are less likely to develop the disease, researchers have reported in a finding that reinforces earlier observations and offers potential paths to treatment. Dr. William Scott of the University of Miami Miller School of Medicine, who led the study, said the findings point clearly to dopamine -- a message-carrying chemical in the brain that falls to low levels in Parkinson's.
November 15, 1989 | From Times wire services
Researchers said today that a new drug dramatically slows the progression of Parkinson's disease and should be used in all patients with early stages of the debilitating nerve illness. Based on preliminary results of a large-scale study, the researchers said the drug deprenyl delays the onset of advanced symptoms of Parkinson's by at least one year and is remarkably safe. Parkinson's is a degenerative disease of the nervous system that mostly strikes people over 40.
An unexpected and potentially significant new approach to the treatment of Parkinson's disease has been discovered by researchers at Johns Hopkins University in Baltimore. Neurologist Mahlon R. DeLong and his colleagues report today in the journal Science that destroying a small number of cells in a particular region of the brain of monkeys produces "dramatic and immediate" improvement in the animals' conditions.
February 4, 1991 | From Times Staff and Wire Reports
Animal studies may have uncovered a new route for developing drugs to slow or halt the debilitating progression of Parkinson's disease, researchers from the German drug company Schering AG reported last week. The researchers said in the journal Nature that they have found drugs that block the so-called NMDA receptors on the surface of rat brain cells and thereby protect the cells from the harmful effects of a chemical known to cause symptoms like Parkinson's.
Los Angeles Times Articles